[go: up one dir, main page]

MX2023012723A - Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares. - Google Patents

Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.

Info

Publication number
MX2023012723A
MX2023012723A MX2023012723A MX2023012723A MX2023012723A MX 2023012723 A MX2023012723 A MX 2023012723A MX 2023012723 A MX2023012723 A MX 2023012723A MX 2023012723 A MX2023012723 A MX 2023012723A MX 2023012723 A MX2023012723 A MX 2023012723A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutical compositions
drug delivery
delivery systems
ocular diseases
Prior art date
Application number
MX2023012723A
Other languages
English (en)
Inventor
Cheng - Wen Lin
Sevgi Gurkan
Angela Dawn Glendenning
Original Assignee
Perfuse Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfuse Therapeutics Inc filed Critical Perfuse Therapeutics Inc
Publication of MX2023012723A publication Critical patent/MX2023012723A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se refiere a un implante ocular biodegradable que comprende un polímero biodegradable que contiene un compuesto tal como Edonentán, o una sal farmacéuticamente aceptable del mismo. También se divulgan métodos de tratamiento de enfermedades oculares con el implante ocular biodegradable y métodos de preparación de los mismos.
MX2023012723A 2021-04-30 2022-04-29 Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares. MX2023012723A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182559P 2021-04-30 2021-04-30
US202163287737P 2021-12-09 2021-12-09
PCT/US2022/027048 WO2022232588A1 (en) 2021-04-30 2022-04-29 Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Publications (1)

Publication Number Publication Date
MX2023012723A true MX2023012723A (es) 2024-02-08

Family

ID=83848732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012723A MX2023012723A (es) 2021-04-30 2022-04-29 Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.

Country Status (10)

Country Link
US (2) US11786510B2 (es)
EP (1) EP4329753A4 (es)
JP (1) JP2024515826A (es)
KR (1) KR20240004643A (es)
AU (1) AU2022264036A1 (es)
BR (1) BR112023022705A2 (es)
CA (1) CA3218251A1 (es)
IL (1) IL307997A (es)
MX (1) MX2023012723A (es)
WO (1) WO2022232588A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118203574A (zh) 2019-10-30 2024-06-18 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
EP4329810A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics Inc TREATMENT OF EYE DISEASES WITH ENDOTHELIN RECEPTOR ANTAGONISTS

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020784A1 (en) 1992-04-10 1993-10-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A microneedle for injection of ocular blood vessels
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
WO2002062343A2 (en) 2001-02-02 2002-08-15 Merck Patent Gmbh PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
BRPI1013904A2 (pt) 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
WO2010144477A2 (en) 2009-06-12 2010-12-16 Auspex Pharmaceuticals, Inc. Sulfonylurea modulators of endothelin receptor
EP2558104A4 (en) 2010-04-12 2013-12-11 R Tech Ueno Ltd METHOD AND OPHTHALMIC COMPOSITION FOR TREATING RETINAL DISEASE
CN109602691A (zh) 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
CA2926515C (en) 2013-10-31 2020-11-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
RU2667640C1 (ru) 2013-12-19 2018-09-21 Тассос ГЕОРГИУ Композиции омега-3 жирных кислот для лечения заболеваний, вызывающих поражение нервной системы
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
CA2986692A1 (en) * 2015-05-29 2016-12-08 Edge Therapeutics, Inc. Compositions and methods for reducing visual loss
CN108883070A (zh) 2015-07-23 2018-11-23 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017217967A1 (en) 2016-06-13 2017-12-21 Noveome Biotherapeutics, Inc. Novel methods for delivering therapeutic agents to the eye via nasal passages
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
SG11201912267SA (en) 2017-06-19 2020-01-30 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
US10905770B2 (en) * 2017-07-17 2021-02-02 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
WO2019210194A1 (en) 2018-04-26 2019-10-31 Vitrisa Therapeutics, Inc. Pegylated compositions for ocular use, and methods thereof
CA3132635A1 (en) 2019-03-05 2020-09-10 Aerie Pharmaceuticals, Inc. Pharmaceutical compositions for treating ocular diseases or disorders
CN118203574A (zh) 2019-10-30 2024-06-18 珀弗斯治疗股份有限公司 使用内皮素受体拮抗剂治疗眼部疾病
AU2021217358A1 (en) 2020-02-06 2022-09-08 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
EP4329810A4 (en) * 2021-04-30 2025-02-26 Perfuse Therapeutics Inc TREATMENT OF EYE DISEASES WITH ENDOTHELIN RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
US20230105507A1 (en) 2023-04-06
JP2024515826A (ja) 2024-04-10
US11786510B2 (en) 2023-10-17
EP4329753A1 (en) 2024-03-06
IL307997A (en) 2023-12-01
BR112023022705A2 (pt) 2024-01-16
WO2022232588A1 (en) 2022-11-03
US20230414577A1 (en) 2023-12-28
CA3218251A1 (en) 2022-11-03
KR20240004643A (ko) 2024-01-11
EP4329753A4 (en) 2025-02-26
AU2022264036A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
PH12021553107A1 (en) Benzisoxazole sulfonamide derivatives
MX2019011491A (es) Formulaciones de niraparib.
PH12021551635A1 (en) Hexone glucokinase inhibitor and use thereof
CY1109425T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων
CR20210201A (es) Nuevos compuestos antihelmínticos
PH12020550341A1 (en) Niraparib formulations
TWI327573B (en) 6-11 bicyclic ketolide derivatives
MX2012007410A (es) Compuestos antivirales novedosos.
MX2023012723A (es) Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.
MX2013014461A (es) Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas.
MX2022013865A (es) Materiales sintéticos similares a los lípidos para la administración al cerebro.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
PH12021551232A1 (en) Haloallylamine compounds and application thereof
AU2019301069A8 (en) Mixing/administration system for vaccines and medicaments
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
MX2023001572A (es) Formas farmaceuticas sólidas de palbociclib.
EP4494705A3 (en) Non-peptide oxytocin receptor agonists
WO2023150619A3 (en) Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
MX2024010408A (es) Dihidroquinazolinonas y analogos relacionados para la inhibicion de yap/taz-tead.
NZ788204A (en) Amorphous pharmaceutical compositions of abiraterone acetate
WO2025010288A3 (en) Hyaluronic acid based drug delivery systems
TW202510888A (zh) 包含托利那泮(tolinapant)之醫藥組合物及包裝
WO2022146355A3 (en) Pharmaceutical capsule compositions of alogliptine